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Abstract
Background: Attention-deficit/hyperactivity disorder (ADHD) is a psychosocially impairing and cost-intensive
mental disorder, with first symptoms occurring in early childhood. It can usually be diagnosed reliably at preschool
age. Early detection of children with ADHD symptoms and an early, age-appropriate treatment are needed in order
to reduce symptoms, prevent secondary problems and enable a better school start. Despite existing ADHD
treatment research and guideline recommendations for the treatment of ADHD in preschool children, there is still a
need to optimise individualised treatment strategies in order to improve outcomes. Therefore, the ESCApreschool
study (Evidence-Based, Stepped Care of ADHD in Preschool Children aged 3 years and 0 months to 6 years and 11
months of age (3;0 to 6;11 years) addresses the treatment of 3–6-year-old preschool children with elevated ADHD
symptoms within a large multicentre trial. The study aims to investigate the efficacy of an individualised stepwise-
intensifying treatment programme.
Methods: The target sample size of ESCApreschool is 200 children (boys and girls) aged 3;0 to 6;11 years with an
ADHD diagnosis according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) or a
diagnosis of oppositional defiant disorder (ODD) plus additional substantial ADHD symptoms. The first step of the
adaptive, stepped care design used in ESCApreschool consists of a telephone-assisted self-help (TASH) intervention
for parents. Participants are randomised to either the TASH group or a waiting control group. The treatment in step
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2 depends on the outcome of step 1: TASH responders without significant residual ADHD/ODD symptoms receive
booster sessions of TASH. Partial or non-responders of step 1 are randomised again to either parent management
and preschool teacher training or treatment as usual.
Discussion: The ESCApreschool trial aims to improve knowledge about individualised treatment strategies for
preschool children with ADHD following an adaptive stepped care approach, and to provide a scientific basis for
individualised medicine for preschool children with ADHD in routine clinical care.
Trial registration: The trial was registered at the German Clinical Trials Register (DRKS) as a Current Controlled Trial
under DRKS00008971 on 1 October 2015. This manuscript is based on protocol version 3 (14 October 2016).
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Background
Attention-deficit/hyperactivity disorder (ADHD) is a
highly prevalent, early-onset, persistent neurodevelopmen-
tal disorder, which is associated with psychosocial func-
tional impairment and a markedly reduced subjective
health-related quality of life [1–3]. According to Diagnos-
tic and Statistical Manual of Mental Disorders, Fifth Edi-
tion (DSM-5) or International Classification of Diseases,
Tenth Edition (ICD-10) criteria, it is characterised by age-
inappropriate, pervasive and persistent inattentiveness,
impulsivity and/or motor restlessness [4, 5]. ADHD symp-
toms can be observed as early as the preschool years, with
an estimated prevalence of 1.5–6% among preschool chil-
dren [6, 7]. For the diagnosis of ADHD, clinically relevant
functional impairment must be present in different set-
tings, e.g. in the family and at preschool. In addition, co-
morbidity in preschool children with ADHD is common,
with oppositional defiant disorder (ODD), communication
disorder and anxiety disorders being the most prevalent
comorbid conditions [8]. Early interventions have been
shown to be particularly helpful and might prevent the de-
velopment of secondary symptoms as well as school fail-
ure [9–11]. International and national treatment
guidelines [12–14] recommend a combination of multiple,
individually adapted treatment components (i.e. multi-
modal therapy). However, compared with school-age chil-
dren, treatment with immediate-release methylphenidate
has been shown to be less effective in preschool children
(i.e. effect sizes were considerably smaller), to cause more
adverse events and to be less accepted by parents [15]. In
contrast, psychosocial treatment may be most powerful at
this early age, as it can positively influence parental scaf-
folding during early self-regulation development and pre-
vent the development of coercive cycles of negative
parent-child interactions. Accordingly, clinical guidelines
recommend psychosocial interventions in the family and
the preschool as the treatment of choice for preschool
children with ADHD [12–14].
Parent counselling and parent management train-
ing have been found to be effective treatments for
children of this age group [12, 16, 17]. Recent meta-
analyses on the efficacy and effectiveness of psycho-
social interventions in preschool children with
disruptive behaviour disorders (DBD), including
ADHD, showed medium to large effects on child be-
haviour outcomes. Based on 13 studies, Charach
et al. [18] found a moderate overall effect (standar-
dised mean difference [SMD] = 0.75) of parenting
training on parent-reported DBD symptoms; the ef-
fect size for core symptoms of ADHD was SMD =
0.77 (five included studies). Similarly, a meta-analysis
of 36 randomised control trials (RCTs) on a broader
range of psychosocial interventions resulted in a
large overall effect on parent-, teacher- and
observer-reported DBD symptoms (Hedges’ g = 0.82)
and a medium effect (g = 0.61) on hyperactivity/im-
pulsivity symptoms in particular [19]. The analysis
included behavioural and non-behavioural treat-
ments, with the former showing significantly larger
effects [19] . Even though clinical guidelines recom-
mend preschool interventions, so far, preschool
teacher training as well as preschool-based interven-
tions are rare. The Cologne group led by Döpfner
reported that their indicated prevention programme
addressing preschool teachers was effective [9, 20,
21]. The measured effects were largely maintained at
1-year follow-up (e.g. [9, 22]).
However, previous studies in preschool children
with ADHD are subject to some limitations. For in-
stance, the evidence regarding the value of these in-
terventions is limited to unblinded ratings made by
individuals who are likely to be invested in the treat-
ment success. Evidence of efficacy from well-
controlled trials using blinded assessments of
outcomes is still lacking [23]. Furthermore, the valid-
ity of the available RCTs is limited by the design
characteristics, as most of the RCTs used no treat-
ment as a control condition, rather than treatment as
usual (TAU) or non-specific support. Therefore, some
of these results cannot be generalised [18, 19].
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Another critical issue in the treatment of preschool
children with ADHD is that unfortunately, not all par-
ents are willing or able to procure treatment for their
children. Frequent reasons why parents do not start or
complete interventions include a lack of problem aware-
ness, a lack of availability of psychotherapy, or other
problems such as transport, childcare, work commit-
ments, financial burden, or stigma (e.g. [24, 25]). Besides
and despite these treatment barriers, the need for inter-
vention still exceeds the number of available treatment
options, and treatment resources are sparse [24]. There-
fore, it is important to focus on therapies and dissemin-
ation methods that help to overcome these barriers.
There is evidence that self-directed, bibliographic inter-
ventions and telephone- or web-based assistance might
be one way forward [18, 26, 27]. Self-directed interven-
tions have been shown to be effective in reducing
parent-rated externalising behaviour problems [28, 29].
Some studies indicate that the effects of such interven-
tions may be improved by minimal therapeutic support
(e.g. by telephone; see [28]). For example, Kierfeld et al.
[30] successfully demonstrated the effects of a
telephone-assisted self-help (TASH) intervention for
parents of preschool children with ADHD and other
externalising behaviour problems. The effects were
maintained at 1-year follow-up [31]. An effectiveness
study on a TASH intervention for parents of 6–12-year-
old children with ADHD found a significant reduction
of ADHD and comorbid symptoms under routine care
conditions [32]. Moreover, TASH for parents was found
to enhance effects of methylphenidate treatment in a
sample of children with ADHD [33]. Interestingly, be-
havioural and non-behavioural TASH interventions
seem to have similar effects [34].
An open research question is which of the different
treatment components (e.g. behaviour therapy, self-
directed interventions) should be offered following ob-
ligatory psychoeducation, and in which order. In this re-
spect, a stepped care approach in which treatment is
individually adapted according to symptom strength, co-
morbid symptoms, specific family needs and treatment
response is suggested [12]. However, empirical evidence
for the efficacy of adaptive treatment strategies for pa-
tients with an ADHD diagnosis in general, and in pre-
school children in particular, is sparse. A study assessing
an adaptive multimodal treatment in school-age children
found that both behaviour therapy and a combination of
behaviour therapy and pharmacotherapy are effective in
the treatment of ADHD [35], with effects persisting at
an 18-month follow-up [36]. Whereas the efficacy of dif-
ferent singular interventions is also well documented in
preschool children, a stepwise approach with individua-
lised adaptive treatment strategies has not been empiric-
ally validated for this age group. Therefore, a stepped
care approach for 3–6-year-old preschool children is be-
ing evaluated within the trial ESCApreschool (Evidence-
Based, Stepped Care of ADHD in Preschool Children
aged 3 years and 0months to 6 years and 11months of
age (3;0 to 6;11 years). The results aim to improve the
knowledge about individualised treatment strategies for
preschool children with ADHD. The evaluation of a
stepwise approach in routine care is of particular im-
portance for clinical practice.
Methods and Design
ESCApreschool is part of a multicentre consortium
studying stepped care approaches for the treatment of
ADHD along the lifespan (ESCAlife: Evidence-Based
Stepped Care of ADHD along the Lifespan, coordinator
Tobias Banaschewski). ESCAlife encompasses stepped
care designs in different age groups (preschool age,
school age, adolescents, adults), each focusing on the dif-
ferent specific needs in the respective life phases, includ-
ing 6–12-year-old school children (ESCAschool [37]),
12–17-year-old adolescents (ESCAadol [38]) and 16–45-
year-old adults (ESCAlate [39]). With regard to design
and methodology, the single studies overlap to allow for
the examination of selected research questions across all
age groups.
Objectives, study design and trial flow
ESCApreschool aims to examine the efficacy of an indi-
vidualised stepwise-intensifying treatment approach
based on evidence-based behavioural interventions in
patients with ADHD or patients with ODD and add-
itional ADHD symptoms, aged 3;0 to 6;11 years, who at-
tend preschool. Different treatment strategies are
investigated for children who respond to a low-threshold
TASH intervention and those who do not. A further
question is to determine precisely which families benefit
from the low-threshold TASH intervention or more in-
tensive behaviour therapy and which families do not,
and to identify the predictors and moderators of treat-
ment response. Therefore, the secondary objective is to
examine the predictability of treatment response by psy-
chological and biological variables.
The multicentre study is designed as a stepwise (two
steps) adaptive treatment study including two RCTs. In
the adaptive design, the second step of the trial (step 2)
depends on the outcome of step 1.
Step 1 of the ESCApreschool study consists of a ran-
domised waitlist-controlled trial which provides the par-
ents (and optionally also the preschool teachers) of the
participating children (planned number of N = 200 chil-
dren) with a 3-month TASH intervention. The parents
(and preschool teachers) are randomised to receive this
treatment either immediately at the beginning of the
trial or after a 3-month waiting period.
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The intervention provided in step 2 of the trial de-
pends on the outcome of the low-threshold TASH inter-
vention. If children fully respond to this intervention,
their parents (and preschool teachers) receive TASH
booster sessions in step 2. If children do not or only par-
tially respond to TASH, that is, if they show persisting
ADHD and/or ODD symptoms, they are randomised to
receive either parent management and preschool teacher
training (PMPTT) or TAU. For an overview of the trial
flow, please refer to Fig. 1.
The sample sizes and response rates displayed in the
figure are estimations and therefore differ from the
actual recruitment and response rates.
Step 1 lasts for 3–6 months depending on the alloca-
tion of the participants (3 months in the TASH group; 6
months in the waiting control group, which undergoes a
3-month waiting period followed by the 3-month TASH
intervention period). Step 2 lasts for 6 months, and the
follow-up period lasts for 3 months.
Measurements are taken at T0 and T1 (T0 = screening
of inclusion and exclusion criteria and assessment of
ADHD and ODD criteria; T1 = baseline assessment as
described below). Further measurements ensue after step
1 (T2), after the second treatment phase in step 2 (T3),
and 3 months after the end of the treatment (follow-up
examination; T4). Families who are randomised to the
waiting control group take part in an additional assess-
ment after the waiting period (T2b1). Participants who
discontinue the intervention during one of the treatment
phases are also invited for the follow-up assessment (T4)
in order to monitor their development. Additionally,
data are collected during the therapeutic process.
Clinical assessments of ADHD and ODD symptom se-
verity are completed by trained experienced clinicians
(further referred to as “blinded clinicians”), who are
blind to the patients’ assignment to treatment condition
but not to the assessment time point (T1-T4). The
inclusion of participants into the study, as well as their
classification as full responders or partial/non-
responders to step 1, are based on these clinical inter-
views. For validation purposes, all interviews are re-
corded and a subsample of the recordings is
subsequently rated by a clinician who is blind to both
the treatment condition and the assessment time point.
Trial sites
At the start of the study, a total of six trial centres lo-
cated at departments of child and adolescent psychiatry
at university hospitals in Germany (Cologne, Hamm,
Mannheim, Marburg, Tübingen, Würzburg) contributed
to this multicentre trial.
The leading and coordinating centre of the ESCApre-
school study is Marburg (Principal Investigator [PI]
Katja Becker). Each of the six centres was expected to
enrol between 30 and 40 patients in order to achieve a
total sample size of N = 200 patients. To compensate for
low recruiting numbers, three additional trial centres
were included in 2018 (Aachen [Kerstin Konrad], Göt-
tingen [Luise Poustka], Neuruppin [Michael Kölch]).
The TASH work group at the Cologne University Hos-
pital (Manfred Döpfner, also Co-PI of ESCApreschool)
is responsible for delivering TASH (which is provided
centrally from Cologne for all participants). All other
diagnostic procedures and treatments are provided at
the respective study centres. On-site therapists who have
been trained and who are supervised by the Cologne
work group perform the behaviour therapy. Responsibil-
ity for data management, archiving and monitoring, as
well as biometrics and project management, lies with the
Centre for Clinical Studies in Freiburg.
Participants
A total of 200 girls and boys, aged 3;0 to 6;11 years, with
either a diagnosis of ADHD or substantial ADHD symp-
toms combined with a diagnosis of ODD are the study’s
target group. Inclusion and exclusion criteria are shown
in Table 1 (see Measures section for a more detailed de-
scription of the instruments). These data are assessed at
ESCApreschool STEP 1 : 3-6 months
ADHD/
ODD
3-6y
n=200
T1
TASH
n=100
STEP 2: 6 months Follow-up: 3 months
R
Waiting 
control
n=100
TASH 
n=100
T2b1
T2a
T2b2
n=
180
ADHD/ 
ODD
80%
R
No
ADHD/ 
ODD
20%
TAU
n=72
PMPTT 
n=72
Booster SH 
n=36
T3c
T4
T3a
T3bT0
Fig. 1 Flow chart. ADHD = Attention-Deficit/Hyperactivity Disorder; ODD = Oppositional Defiant Disorder, T0 to T4 = Assessment Time Points; R =
Randomisation; TASH = Telephone-Assisted Self-Help for Parents and Preschool Teachers; PMPTT = Parent Management and Preschool Teacher
Training, TAU = Treatment as Usual, Booster SH = Booster Self-Help
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baseline through an interview gathering baseline charac-
teristics as well as sociodemographic data. Patients are
recruited through the centres’ outpatient clinics, which
are highly experienced in the treatment of ADHD or
preschool children. Further recruitment strategies in-
clude the dissemination of information regarding the
study at local conferences, and by contacting paediatri-
cians, child and adolescent psychiatrists, child and ado-
lescent psychologists and child guidance centres.
Additionally, information is provided to other counsel-
ling centres, ADHD self-help groups and preschool
teachers either in writing, in person, or through lectures.
In Germany, the local health authorities organise a
mandatory health examination for preschool children
shortly before school entry. Therefore, the respective
local health authorities are also informed about the
study. All of these recruitment activities are flanked by
homepage information, local public lectures and re-
peated advertisement actions providing information
about the study (postings, flyers, bus advertisements,
newspaper articles) in order to reach parents directly.
*Some changes have been made since the first version
of the study protocol (9 June 2015). First, we initially
planned an age span of 3;0 to 5;11 years. However, this
resulted in the exclusion of 6-year-olds who were still at-
tending preschool within the overall ESCAlife study.
Thus, this inclusion criterion was changed to 3;0 to 6;11
years (Note to File G005 22 September 2016, positive
Ethics Committee vote 08 November 2016). Second, the
first version of the study protocol comprised an add-
itional inclusion criterion of a time span from at least 9
months before enrolment in primary school. Due to re-
cruitment problems, this criterion was changed to “at-
tending preschool” (Note to File G003 25 May 2016;
positive Ethics Committee vote 3 June 2016). Third, an
inclusion criterion in the first version of the trial proto-
col was the presence of an ADHD diagnosis according
to DSM-5, assessed with a clinician-rated ADHD check-
list (DCL-ADHS). However, after study start, we realised
that at preschool age, the differentiation between a diag-
nosis of ADHD and a diagnosis of ODD plus additional
ADHD symptoms might be blurred. Therefore, this in-
clusion criterion was changed to that mentioned in the
table (Note to file G002, 25 May 2016, positive Ethics
Committee vote 3 June 2016).
Fourth, the initial inclusion criterion “informed con-
sent of preschool teacher” was withdrawn due to the fact
that in some centres, it was not permitted to contact
preschool teachers directly. Therefore, in the present
version of the study protocol, while it is preferable to in-
clude a preschool teacher in the study (if parents agree
to their being contacted), this is not a prerequisite or an
inclusion criterion (Note to File G003 25 May 2016;
positive Ethics Committee vote 3 June 2016). Fifth, ini-
tially, an exclusion criterion was “current medication for
ADHD or other psychotropic medication”. After realis-
ing that this exclusion criterion leads to an exclusion of
severe cases with a current ADHD medication, this cri-
terion was changed to “psychotropic medication of the
child (except for ADHD medication)” (Note to File
G003 25 May 2016, positive Ethics Committee vote 3
June 2016).
This table gives the inclusion and exclusion criteria of
Version 3 of the Trial Protocol (V03, 14. October 2016)
including all amendments G001-G005.
** The comorbid conditions which are defined as ex-
clusion criteria are the same as those for the different
trials within the ESCAlife consortium, including some
diagnoses which are unlikely to appear at preschool age.
Patients are included if they meet the eligibility criteria
(see Table 1). Parents (and, if applicable, preschool
teachers) must give their informed consent and children
their assent for study participation.
Response criteria
The response criteria correspond to the child’s symptom
inclusion criteria (see Table 1). Partial or non-
responders have ADHD (DSM-5) assessed with the
clinician-rated ADHD Checklist (DCL-ADHS) or ODD
(DSM-5) assessed with the clinician-rated ODD Check-
list (DCL-SSV) plus substantial ADHD symptoms (de-
fined by a score of ≥ 0.7 on either of the two subscales
[hyperactivity/impulsivity or inattention] of the DCL-
ADHS). Full responders fulfil neither of these conditions
and no longer have ADHD or ODD with substantial
ADHD symptoms.
Table 1 Inclusion and exclusion criteria
Inclusion
criteria
• Age 3;0 to 6;11 years*
• Attending preschool*
• Exhibiting externalising behaviour problems, that is, either meeting DSM-5 criteria for ADHD on a clinician-rated ADHD checklist
(DCL-ADHS) or meeting DSM-5 criteria for ODD on a clinician-rated ODD-checklist (DCL-SSV) plus substantial attention or hyperactivity/
impulsivity problems (score≥ 0.7 on either the inattention or the hyperactivity/impulsivity subscale of the DCL-ADHS)*
• Informed consent of the parents (and, if applicable, the preschool teacher*) and assent of the child
Exclusion
criteria
• Intelligence quotient (IQ) < 80
• Comorbidity: pervasive developmental disorder, schizophrenia, bipolar disorder, severe depressive episode**
• Lack of sufficient German-language skills of parents
• Psychotropic medication of the child (except for ADHD medication)*
• Child’s participation in a regular intensive behaviour therapy (on a weekly or fortnightly basis)
Becker et al. Trials           (2020) 21:56 Page 5 of 19
Data handling
All legal requirements pertaining to the protection of
personal data have been met. Upon enrolment, every
participating child is assigned with a study-specific iden-
tification code. To ensure complete pseudonymisation,
all study data from patients and their parents are stored
under their assigned code. This is not shared, with the
sole exception of transmission of contact details to
members of the Cologne group providing the TASH
intervention, following consent from participating par-
ents. Only the PI and the study coordinators at each site
have access to the patient identification list. The Clinical
Trials Unit (CTU) Freiburg provides an electronic re-
mote data entry system (RDE-LIGHT), in which infor-
mation is entered by specifically trained personnel under
the study code. To prevent unauthorised access to confi-
dential participant information, built-in security features
encrypt all data before transmission to and from the
CTU. Users who enter data into the system are regis-
tered with the CTU and receive an individual ID and
password to gain access to the system, in order to pre-
vent unauthorised access to patient data. Data process-
ing at the CTU is limited to authorised personnel who
are familiar with the data handling procedures according
to the study protocol.
Interventions
Telephone-assisted self-help (TASH)
In step 1, all participants receive a 3-month behaviour
therapy-oriented TASH intervention for parents of chil-
dren with externalising behaviour problems. Addition-
ally, if both the parents and the preschool teacher agree,
preschool teachers also receive the intervention [40, 41].
The intervention is based on the Therapy Programme for
Children with Hyperactive and Oppositional Problem Be-
haviour (Therapieprogramm für Kinder mit hyperkine-
tischem und oppositionellem Problemverhalten – THOP
[42]) and the German self-help book Wackelpeter &
Trotzkopf [43]. Both the parent and the preschool
teacher programme consist of self-help booklets on
externalising behaviour problems and behaviour modifi-
cation techniques, which are sent to the participants
through the post. Additionally, they receive telephone
consultations with a therapist in advanced training for
child and adolescent psychotherapy, who is supervised
by senior supervisors. These consultations serve to sup-
port the parents and preschool teachers with the imple-
mentation of the interventions into their daily routines
[40, 41].
Parent TASH programmes similar to that used in the
present study have already been shown to reduce behav-
iour problems in preschool- and school-age children
(e.g. [30, 32–34]). For the current study, the parent
booklets were revised and adapted to address the specific
needs of families of preschool children. The parents re-
ceive eight booklets and ten telephone consultations,
each lasting for approximately 30 minutes. The TASH
programme for the preschool teachers consists of four
newly developed booklets and four telephone consulta-
tions of up to 60minutes each. The appointments for
the telephone consultations are set on an individual
basis. The contents of the booklets are described in
Table 2 and Additional file 1: Table S1.
For the preschool teachers, the interventions originally
developed for the family environment have been adapted
to the preschool environment. Moreover, the booklets
for the preschool teachers cover information on improv-
ing environmental conditions, which might help the
child to deal with his or her behaviour problems, and on
constructive cooperation with parents (see Additional
file 1: Table S1).
If children are full responders to the TASH inter-
vention, two additional telephone consultations for
the parents and, optionally, one additional telephone
Table 2 Overview of the telephone-assisted self-help (TASH) booklets for parents of preschool children
Title Content
1 Taking a close look at our problems Defining individual problem behaviour and psychoeducation regarding coercive parent-child
interactions
2 What is ADHD? Psychoeducation on ADHD symptoms in preschoolers, associated problems, reasons for ADHD,
the developmental course of ADHD, and treatment alternatives
3 Learning to like each other again Encouragement of positive parent-child interactions by focusing on positive traits and positive ex
periences with the child and by actively creating more positive interactions and experiences with
the child
4 Clear daily structures – gathering energy and
implementing clear rules
Implementation of well-structured daily and weekly routines, strategies of parental stress manage
ment, and reflecting on and implementing family rules
5 Make effective requests and do not skimp on
praise
Making effective requests, praise and positive consequences for following rules
6 The need for consequences Appropriate negative consequences for breaking rules
7 If praise is not enough: reward systems Implementation of reward symptoms
8 Learning how to play attentively Helping the child to stay attentive when playing
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consultation for the preschool teacher are provided
(Booster TASH).
Parent management and preschool teacher training
(PMPTT)
For children with no or only partial response to TASH,
who are randomised to the PMPTT group, age-
appropriate individually tailored behaviour therapy is pro-
vided in step 2. The 6-month PMPTT encompasses (1)
parent management training, including parent-child inter-
action training, (2) preschool-teacher-focused interven-
tions, including psychoeducation and behavioural
interventions in the preschool, and (3) child-focused
interventions (see Table 3). The primary goal of PMPTT is
to reduce child problem behaviour and to enhance the
parent-child and teacher-child relationship by improving
parents’ skills and teachers’ educational skills. A total of 20
weekly sessions are provided. Parent- and teacher-focused
interventions are based on the THOP [42] and on the PEP
(Prevention Programme for Externalising Problem Behav-
iour; Präventionsprogramm für Expansives Problemverhal-
ten - PEP [44]). Child-focused interventions are based on
the Therapy Programme for the Improvement of Organisa-
tional Skills, Concentration and Impulse Control in Chil-
dren with ADHD (Therapieprogramm zur Steigerung von
Organisationsfähigkeit, Konzentration und Impulskontrolle
Table 3 Overview of the Parent Management Preschool Teacher Training (PMPTT) contents
Introductory therapy components (sessions 1–5)
Parents (+ child) Child Preschool teacher
P1 Getting to know each other and exploration of
current externalising symptoms of the child
C1 Getting to know each other
and exploration of the child
T1 Exploration of current externalising symptoms
of the child in the preschool environment
P2 More specific exploration of the current ADHD
symptoms of the child
C2 Clinical observation of a
structured play situation
T2 Psychoeducation on ADHD
P3 Psychoeducation on ADHD
Basic therapy components (sessions 6–10)
Parents (+ child) Preschool teacher
P4 Focusing on positive experiences with the child T3 Encouragement of positive teacher-child interactions
P5 Implementation of clear rules (optionally together
with the child)
P6 Development of effective requests
P7 Social reinforcement and positive consequences of
following rules
P8 Appropriate negative consequences of breaking
rules
Intensification components (sessions 11–20)
P9 Social reinforcement of non-disturbing behaviour T4 Helping the child to stay attentive when playing
P10
Development of positive play interactions T5 Implementation of clear daily structures
P11
Development of token systems T6 Implementation of clear individual rules and group rules
P12
Development of response cost systems T7 Development of effective requests
P13
Time-out T8 Appropriate positive or negative consequences of following or breaking rules
P14
Strategies of parental stress management T9 Development of token systems or response cost systems
P15
Fostering the child’s strengths and interests and
channelling his or her energy
P16
Helping the child to stay attentive when playing
(participant: child, optionally together with parent)
P17
Management of behaviour problems in public
P18
Consultation regarding non-externalising / emo-
tional problems of the child
If possible, introductory therapy components and basic therapy components should be applied in all families. Intensification components are used depending on
the individual needs of the families
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bei Kindern mit ADHS – THOKI-ADHS [45]). THOP is
the only German treatment programme for ADHD with
established efficacy [42]. PEP has been extensively evalu-
ated in several trials with preschool children with externa-
lising problem behaviour [9]. The PEP programme was
originally developed for the training of parents and
teachers of preschool children in a group format. For
ESCApreschool, PEP materials were adapted for use in an
individual format. PMPTT is conducted by clinical thera-
pists who are trained during a 2-day workshop (see section
on Treatment integrity).
Treatment as usual (TAU)
The other group of partial or non-responders to TASH
receives TAU in step 2, that is, a typical, mostly
guideline-based ADHD preschool intervention. TAU is
usually conducted by the participating centres but may
also be performed by local cooperating institutions (e.g.
child guidance centres, ergo−/occupational therapy,
child and adolescent psychiatrists, psychotherapists). In
the latter case, members of the cooperating institutions
are asked to provide information about their treatment.
To achieve a minimum of conformity, at least four pa-
tient contacts within the treatment period of 6 months
are recommended.
Starting or optimising an additional ADHD pharmaco-
therapy (according to the clinical decision of the treating
physician) is permitted in step 2 in the TAU condition
as well as in the PMPTT condition, but has to be
documented.
Treatment integrity
Treatment integrity is established through qualification
standards for therapists (therapists have completed a
university degree qualifying for training to become a li-
censed child and adolescent therapist, and are currently
in training for psychotherapy with children and clinical
expertise in the treatment of ADHD), study-specific
therapist training, the use of the manualised treatment
programmes and the use of protocol sheets for treat-
ment documentation. TASH and PMPTT treatments are
supervised by senior supervisors to check for adherence
to the manual and study procedures. PMPTT therapists
participate in three supervision sessions per patient.
These sessions are scheduled after therapy sessions 5, 10
and 15, and are conducted either face to face or by tele-
phone. For each patient, at least two video sequences are
discussed with the supervisor. The TASH consultations
are recorded in audio files and supervised regularly.
Informants
ESCApreschool collects information from different per-
spectives and informants: unblinded clinician (e.g. ther-
apist or TASH counsellor), blinded clinician, the
participating parent, the other parent/partner of partici-
pating parent, and, optionally, the preschool teacher.
The blinded clinicians conduct the clinical interviews
with the parents, and are blind to the study condition.
However, in order to minimise heterogeneity in ratings
caused by different assessors, the same clinician should
perform the interviews with a family at the different as-
sessment time points. Therefore, the blinded clinicians
are not blind to the assessment time point.
Additionally, to control for inter-rater reliability, the
ratings of the parent interviews are audio- or videotaped.
A clinician who is blind to both the treatment condition
and the assessment time point rates a random selection
of these interviews. The parent is the biological parent
or guardian of the child, who is involved in the treat-
ment (he or she is therefore not blind to the treatment
condition). If possible, ratings by the child’s preschool
teacher are obtained.
Measures
Main assessment time points
Unless otherwise stated, the primary and secondary out-
come measures are assessed at all four main assessment
time points (T0/T1, T2, T3, T4). Figure 2 gives an over-
view of the measures assessed at the different time
points.
Additional file 2: Figure S1 presents the time schedule
in greater detail, with an overview of outcome measures,
predictors and eligibility criteria.
Primary and secondary outcome measures
Primary outcome measures
The primary outcome is the change in the combined
ADHD and ODD symptom score. This combined symp-
tom score is derived from the blinded clinician-rated
ADHD and DBD Symptom Checklists based on a parent
interview (DCL-ADHS + SSV Parent [46]). The DCL-
ADHS and the DCL-SSV assess symptoms of ADHD or
ODD and conduct disorder, respectively, according to
DSM-5 and ICD-10 criteria. The DCL-ADHS consists of
18 items assessing ADHD symptoms and five items
assessing functioning and psychological strain. The items
on ADHD symptoms can be aggregated into two scales,
inattention (nine items) and hyperactivity/impulsivity
(nine items). The DCL-SSV comprises 28 items belong-
ing to four subscales: ODD (eight items), aggressive-dis-
social problem behaviour (seven items), limited prosocial
emotionality (11 items), and disruptive mood disorder
(five items, three of which are also part of the ODD
scale). For ESCApreschool, we excluded the scale asses-
sing disruptive mood disorder, as the associated symp-
toms are uncommon in preschool children. Moreover,
the DCL-SSV includes five items on functioning and psy-
chological strain. All items are rated on a 4-point Likert-
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type scale ranging from 0 to 3, with higher scores indi-
cating higher symptom severity. Scale scores are com-
puted by averaging the associated item scores. The
DCL-ADHS and the DCL-SSV subscales and total scores
show satisfactory internal consistency (Cronbach’s
α > .68 [46, 63].
We use a combined score of ADHD and ODD, since
the two conditions are highly correlated in preschool
children with ADHD, and the reduction of symptoms of
ADHD and ODD is usually the main objective of treat-
ments in this age group.
Secondary outcome measures
The secondary outcome measures assess (1) ADHD and
DBD symptoms as rated by parents and teachers, (2)
psychosocial impairment, (3) comorbid symptoms and
comorbid mental disorders, (4) quality of life of the child
as perceived by parents, (5) social reactivity, and (6) par-
enting behaviour. All instruments used to assess symp-
toms and impairment are recommended in diagnostic
guidelines for ADHD [12] and are employed in clinical
practice. All secondary outcome measures have been val-
idated both in English and in German and have been
used in previous trials of pharmacological and psycho-
therapeutic interventions as well as in prevention stud-
ies. They have been widely used in children, and
especially in preschool children with ADHD. All instru-
ments provide population-based norms and therefore
enable the calculation of age- and gender-adjusted nor-
malisation rates.
ADHD and DBD symptoms
Parents and preschool teachers rate the symptom sever-
ity of ADHD and DBD on the ADHD Parent and
Teacher Rating Scale for Preschool Children (FBB-
ADHS-V; German: Fremdbeurteilungsbogen für
Vorschulkinder mit Aufmerksamkeitsdefizit−/Hyperakti-
vitätsstörungen [46]) and on the DBD Parent and
Teacher Rating Scale (FBB-SSV; German: Fremdbeurtei-
lungsbogen für Störungen des Sozialverhaltens). The
scales capture symptoms of ADHD or DBD, respectively,
according to ICD-10 and DSM-5. The FBB-ADHS-V
consists of 19 items belonging to the subscales inatten-
tion and hyperactivity/impulsivity. In the version for
younger children (up to the age of 11), the FBB-SSV
comprises 27 items, which can be aggregated into four
subscales: ODD, aggressive-dissocial problem behaviour,
limited prosocial emotionality, and disruptive mood dis-
order. All items are rated on a 4-point Likert-type scale
ranging from 0 to 3, with higher scores indicating higher
symptom severity. Scale scores are computed by aver-
aging the associated item scores. The subscales and the
total score of both the FBB-ADHS and the FBB-SSV
have demonstrated reliability and factorial validity.
Fig. 2 Overview of measures and assessment time points
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Clinical global impression and functional impairment
The clinician-rated Clinical Global Impression Scale
(CGI) is administered using a short clinical interview
[47]. It is a widely used outcome parameter in clinical
trials, measuring disease severity (CGI-severity, CGI-S)
as well as general improvement during treatment (CGI-
improvement, CGI-I). Both the CGI-S and the CGI-I are
rated on a 7-point scale, with higher scores indicating
greater severity or improvement, respectively. The CGI
shows a good inter-rater reliability (.65–.92 [64];) and an
intra-class correlation coefficient of .91 [65].
A German version of the parent-rated Weiss Func-
tional Impairment Rating Scale, which was modified and
adapted for use in preschool-age children, is applied to
measure functional impairment [66, 67]. The modified
German version consists of 40 items, which are rated on
a 4-point Likert-type scale ranging from 0 to 3. Higher
scores indicate greater impairment. The subscales and
total score of the original version and of the modified
German version have shown internal consistency
(α > .80) and factorial validity [66–68]. Moreover, the
original version has demonstrated test-retest reliability,
convergent validity, and responsiveness to change [68].
Comorbid internalising and externalising symptoms
The German version of the parent-rated Child Behavior
Checklist 1½-5 (CBCL 1½-5 [69];; original English ver-
sion: [70]) and the preschool teacher-rated Caregiver-
Teacher Report Form 1½-5 (C-TRF 1½-5; Arbeitsgruppe
Deutsche Child Behavior Checklist, 2002b; original Eng-
lish version: [70]) are questionnaires to assess behav-
ioural problems, emotional problems and somatic
complaints of toddlers and preschool children aged 1½
to 5 years. Both scales comprise 99 items (83 overlapping
items) rated on a 3-point scale ranging from 0 to 2. The
items can be aggregated into several syndrome scales as
well as into three superordinate scales: internalizing
problems, externalizing problems, and total problems.
These superordinate scales are considered in ESCApre-
school. For both the CBCL and the C-TRF, these scales
have demonstrated satisfactory internal consistencies
(α > .80) in German samples [69]. Moreover, analyses in
German samples have provided evidence for the con-
struct validity of the CBCL as well as limited evidence
for the factorial validity of the CBCL internalizing prob-
lems and externalizing problems scales [69].
Quality of life
In evaluating health care with respect to prevention and
treatment, quality of life has emerged as an important
concept. We use the Kiddy-KINDL [53, 71, 72] to assess
subjective generic health-related quality of life in pre-
school children. Results on the reliability of this scale
vary: In a sample of preschoolers aged 4–6 years,
Cronbach’s alpha for the total score varied from .66 to
.70 depending on age and gender [72]. However, in a lar-
ger sample of 3–6-year-old children, a Cronbach’s alpha
of .82 was reported [73].
Callous-unemotional traits and social responsiveness
Callous-unemotional traits are assessed with five items
of the prosocial behaviour scale and the peer problems
scale of the Strengths and Difficulties Questionnaire
(SDQ [74]) and three items of the callous-unemotional
dimension of the Antisocial Process Screening Device
(APSD-CU [75], which were combined into a joint
measure. The items are rated on a 3-point scale ranging
from 0 to 2. Pasalich et al. [51] also combined items of
the SDQ and the APSD, but used more items. They
found satisfactory internal consistencies across mother,
father and child ratings of their measure (range of α =
0.69–0.87).
Social responsiveness is assessed using a shortened
16-item version of the Social Responsiveness Scale
(SRS-short [76]). The items of this questionnaire are
rated on a 4-point scale ranging from 0 to 3. The
long version of the SRS shows high internal
consistency (α = 0.91–0.97) as well as satisfactory test-
retest reliability, inter-rater reliability, convergent val-
idity and discriminative validity [60].
Parenting behaviour
Positive parenting behaviour is assessed using a German
questionnaire covering positive parenting skills (Fragen
zum Erziehungsverhalten, FZEV; Naumann, Kuschel
et al., 2007). This questionnaire comprises 13 items
rated on a 4-point scale ranging from 0 to 3, with higher
scores indicating more positive parenting behaviour. The
scale shows satisfactory internal consistency (mother rat-
ings: α = 0.85; father ratings: α = 0.87 [77]). For the as-
sessment of negative parenting behaviour, we apply the
respective 13-item scale of the Questionnaire on Positive
and Negative Parenting Behaviour (German: Fragebogen
zum positiven und negativen Erziehungsverhalten, FPNE
[55]). The items of this scale are rated on a 4-point scale
ranging from 1 to 4, with higher scores indicating more
negative parenting behaviour. The scale is internally
consistent (α = 0.78).
Additionally, to assess parents’ perceived sense of
competency concerning challenging parenting situa-
tions, we employ a modified German Version of the
Problem Setting and Behaviour Checklist (German:
Verhalten in Risikosituationen, VER [77]). The 27
items of this questionnaire are rated on a 4-point
scale ranging from 1 to 4, with higher scores indicat-
ing a stronger sense of competency. The scale has
demonstrated high internal consistency (mother rat-
ings: α = 0.92, father ratings: α = 0.94 [77]).
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Treatment satisfaction
For the assessment of satisfaction with the treatment,
treatment-specific parent satisfaction questions were de-
veloped (e.g. for the assessment of satisfaction with
TASH). These are assessed as part of the clinical inter-
view at T2 and T3.
Feasibility and adherence measures
Besides the outcome measures used at all of the main
assessment time points (T1 to T4), the following mea-
sures are used to assess feasibility and adherence:
(1) Clinical Feasibility Rating Scale (newly developed)
to rate the feasibility of the TASH and PMPTT
interventions (at T2 and T3);
(2) Clinical Adherence Rating Scale (newly developed)
to assess the adherence of the patient, the parents
and preschool teachers during the interventions (at
T2 and T3).
Assessment of potential moderators of treatment
response
The following potential moderators of treatment re-
sponse are analysed: (1) age, (2) gender, (3) socioeco-
nomic status, (4) ADHD symptom severity, (5) comorbid
symptoms, (6) intelligence, (7) parental depression, anx-
iety and stress (Depression, Anxiety and Stress Scale,
DASS; Cronbach’s α = 0.89–.96, test-retest reliability r =
0.71–.81, validity [57, 78]), and (8) parental ADHD
(ADHD Self-Rating Scale, German: ADHS-Selbstbeurtei-
lungsskala, ADHS-SB; test-retest reliability r = 0.78–.89;
Cronbach’s α = 0.72–.9, validity [62, 79]).
Psychometric data
The following variables are assessed using a clinical
interview with the parent during the diagnostic assess-
ment at T0 and T1 and considered as possible predictors
of treatment outcome: sociodemographic data of the
child and the parent (e.g. child age, educational level of
the parent or guardian), data on early child development
(six items), temperament (13 items; Junior Temperament
and Character Inventory [JTCI] 3–6 [59]), irritability
(seven items; Affective Reactivity Index [ARI-Parent]
[80]), and life events (14 items). Additionally, we employ
the German version of the Family Adversity Index (FAI),
adopted from the German Mannheimer Elterninterview
[81]; original English version: [82, 83]). To measure par-
ental aggression, we use the anger control scale of the
German Elternfragebogen zum Umgang mit Ärger (FB-Ä)
[Götz-Dorten, A. (unpublished) 2013; Department of
Child and Adolescent Psychiatry, Psychosomatics and
Psychotherapy, University of Cologne], which is a modi-
fied version of the 12-item form of the Aggression Ques-
tionnaire [84, 85]. The clinical checklist Diagnose-
Checkliste zum Screening psychischer Störungen (DCL-
SCREEN; taken from the DISYPS-III [46]) is used to as-
sess comorbid symptoms of depression (seven items),
anxiety (ten items), autism spectrum disorder (four
items), other neurodevelopmental disorders (six items),
obsessive-compulsive disorder (two items) and tic disor-
ders (one item). Based on a modified questionnaire by
Piacentini et al. [86], the therapists additionally report
their expectation of treatment benefit (three items) for a
family. Moreover, the participating parents provide in-
formation about their own treatment expectations.
Furthermore, after every therapy session of step 1 and
step 2, the therapist rates the treatment integrity (13
self-developed items), the treatment adherence of the cli-
ent (ten items; eight items for TASH only), and current
ADHD symptoms of the child (four items; shortened
version of the German ADHD Questionnaire [87].
At the beginning of the study (T0/T1), children
complete four subtests of the Wechsler Preschool and
Primary Scale of Intelligence (WPPSI-III) to assess their
IQ [49]. The 3-year-old children work on the scales Re-
ceptive Vocabulary, Comprehension, Block Design and
Object Assembly, while the 4–6-year-olds complete the
subtests Word Reasoning, Vocabulary, Matrix-Reasoning
and Block Design.
Biological data
Transcranial sonography (TCS) is used to assess bio-
logical predictors of treatment response, especially in
younger children. This is part of the transversal project
ESCAbrain, which assesses biological data in all ESCA-
life trials (see also [37–39]). Using TCS, the size of the
echogenic region of the substantia nigra is assessed. In
children, ADHD-associated hyperechogenicity of the
substantia nigra has consistently been reported and has
previously been identified as a potential biological
marker of ADHD [88, 89]. TCS is a non-invasive
method for the visualization of deep brain structures,
such as the substantia nigra, through the intact skull.
Ultrasound waves are reflected depending on tissue
composition, resulting in different echogenicity of nuclei
and ventricular system [38]. The method has no harmful
side effects. Of particular interest is the mesencephalic
scanning plane, including brainstem, substantia nigra
and raphe nuclei. In terms of clinical implications, TCS
can aid differential diagnosis (e.g. in movement disorders
[90]) and has shown promise in predicting treatment re-
sponse in psychiatric disorders in adult patients. As yet,
no study has explored whether TCS can predict the ef-
fectiveness of non-pharmacological interventions. TCS is
optional for the patients. As a well-tolerated investiga-
tion, it offers fast, non-invasive, targeted imaging in this
age group in which magnetic resonance imaging (MRI)
is not feasible or practical.
Becker et al. Trials           (2020) 21:56 Page 11 of 19
Furthermore, saliva samples are collected before step 1
(T0/T1) and after step 2 treatment (T3) to determine
predictive genetic and epigenetic patterns. These saliva
samples are collected according to standard protocol of
the ESCAmark subproject, which coordinates biosam-
pling across the ESCAlife consortium. Samples are
stored at − 80 °C and will be analysed after recruitment
closure of all RCTs within ESCAlife. Samples will be
used according to the ethics vote and data management
plan of ESCAmark that will be published separately.
Randomisation procedure
Central randomisation with a 1:1 treatment ratio, analo-
gous to the other ESCA trials [37–39], is performed by
the CTU at the University Medical Centre Freiburg via
fax, using block randomisation with variable block
length to ensure concealment of randomisation. Ran-
domisation is stratified by centre. The randomisation re-
quest form contains the study-specific patient
identification number, year of birth and the confirmation
of ADHD above the cut-off. The CTU reviews the pa-
tient’s details on the randomisation fax and performs the
randomisation if the data on the fax are appropriate and
complete.
Quality assurance and monitoring
The monitoring is performed by the clinical research as-
sociates (CRAs) of the CTU. Adapted monitoring is ac-
complished according to Good Clinical Practice (ICH-
GCP E6) and standard operating procedures (SOP). This
verifies that patients’ rights and well-being are protected,
that reported trial data are accurate, complete and verifi-
able from source documents, and that the trial is con-
ducted in compliance with the currently approved
protocol/amendment, with GCP and with the applicable
regulatory requirements to ensure safety and integrity of
clinical trial data. In this trial, all trial-specific monitor-
ing procedures, monitoring visit frequency and the ex-
tent of source data verification (SDV) are predefined in a
specific monitoring manual.
The investigator accepts monitoring visits before, dur-
ing and after the clinical trial. Prior to the trial, a pre-
trial telephone consultation and a site initiation visit at
each site are conducted in order to train and introduce
the investigators and their staff to the trial protocol, es-
sential documents and related trial-specific procedures,
ICH-GCP and national/local regulatory requirements.
During the trial, the monitor visits the site regularly
depending on the recruitment rate and quality of data.
During these on-site visits, the monitor verifies that the
trial is being conducted according to the trial protocol,
trial-specific procedures, ICH-GCP and national/local
regulatory requirements. Moreover, the monitor checks
that signed informed consent has been provided, and
verifies the eligibility of patients, completeness of pri-
mary endpoint questionnaires, treatment compliance,
and documentation. The monitor also performs source
data verification to ensure that clinical trial data are re-
corded and documented in the source data and that case
report forms (CRFs) are complete and accurate. In the
case of data quality problems or a high number of proto-
col violations at individual sites, the extent of source
data verification and frequency of monitor visits is
adapted accordingly.
The investigator must maintain source documents for
each patient in the trial, consisting of case and visit
notes (hospital or clinic medical records) containing
demographic and medical information, laboratory data,
and the results of any other tests or assessments. All in-
formation recorded on CRFs must be traceable to source
documents in the patient’s file. The investigator must
also keep the original signed informed consent form (a
signed copy is given to the patient).
The investigator must give the monitor access to all
relevant source documents to confirm their consistency
with the CRF entries.
An independent Data Monitoring Committee (DMC),
composed of Prof. Dr. H. J. Freyberger, Prof. Dr. A.
Rothenberger and Prof. Dr. J. Schmitt, advises the trial
sponsor on patient safety and measures to ensure the
credibility and integrity of the ongoing trial.
Stopping rules
Inclusion in the study is not possible without written in-
formed consent of parents/guardians. If a preschool
child requires inpatient treatment or needs a different
kind of treatment for health reasons according to the
judgment of the attending physician, the child will be ex-
cluded from the study. Study exclusion will also occur if
any other factors arise which affect the child’s well-
being. The Ethics Committee will be informed immedi-
ately in the case of severe events during the conduct of
the trial. Global stopping rules for the trial or closing of
a centre include the emergence of data leading to a revi-
sion of the risk-benefit ratio, ongoing failure of recruit-
ment, or repeated violations of standard GCP rules or of
the study protocol. For a decision on the termination of
the trial or on closing a participating centre, agreement
between the study coordinator, PIs, site investigators,
DMC members, the responsible Ethics Committee and
the CTU Freiburg is intended.
Sample size and power calculations
The whole stepped care design is primarily powered for
the two RCTs in step 1 and step 2. Based on the results
of previous studies, an effect size of d = 0.5 is expected
for the RCT in step 1 (TASH compared to a waitlist
control group). Kierfeld et al. [30] found a moderate to
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large effect (d = 0.79) of a TASH intervention compared
to a waitlist control group on parent-rated ADHD symp-
toms. Both the intervention and the outcome measure
were similar to those used in this current trial. Effect
sizes of about SMD = 0.75 were found for parent man-
agement training interventions, mainly compared to
waiting groups in children with disruptive behaviour
problems, using unblinded parent ratings [18]. However,
reported effects sizes are smaller when blinded ratings
are applied [23]. Therefore, we expect an effect size of
d = 0.5 for the primary outcome for the randomisation
comparing PMPTT with TAU in step 2.
The calculation of the sample size (software: STPLAN
Version 4.3) is based on the primary endpoint of step 2
(ADHD/ODD change score from T2 to T3). Using a
two-sided t test with a power of 80% at a significance
level of 5%, 64 patients with non-missing data per group
are required to detect a difference when the true effect
size is d = 0.5. To account for the possibility that some
patients (10%) will have incomplete data at T3, in total,
144 partial or non-responders should be randomised at
step 2. We assume that about 20% (n = 36) will show a
full response after step 1 [30] and that a group of 10%
will have dropped out from T1 to T2. Therefore, 180/
0.9 = 200 patients should be randomised at T1 (step 1).
Given 180 patients with complete data and a presumed
true effect size of d = 0.5, the power to detect a differ-
ence is 92%. We assume that about 300 patients will
need to be screened for study participation.
Statistical analyses
Before the inclusion of the first patient, a detailed statis-
tical analysis plan (SAP) was prepared. This will be com-
pleted during the ‘blind review’ of the data, at the latest.
If the SAP contains any changes to the analyses outlined
in the trial protocol, they will be marked as such, and
reasons for amendments will be given.
All statistical programming for analysis will be per-
formed with the Statistical Analysis System (SAS Insti-
tute, Cary, NC, USA).
Definition of populations included in the analyses
The primary analysis will be conducted according to the
intention-to-treat (ITT) principle. This means that the
patients will be analysed in the treatment arms to which
they were randomised, irrespective of whether they re-
fused or discontinued the treatment or whether other
protocol violations become apparent.
The per-protocol (PP) population is a subset of the full
analysis set (FAS) and is defined as the group of patients
who had no major protocol violations, received a prede-
fined minimum dose of the treatment and underwent
the examinations required for the assessment of the end-
points at relevant, predefined times. The analysis of the
PP population will be performed for the purpose of a
sensitivity analysis.
Safety analyses will be performed in the safety popula-
tion. Patients in the safety population are analysed as be-
longing to the treatment arm defined by treatment
received. Patients are included in the respective treat-
ment arm if treatment was started/if they received at
least one dose of trial treatment.
Patient demographics/other baseline characteristics
Demographic and other baseline data (including disease
characteristics) will be summarised descriptively using
all documented patients. Continuous data will be sum-
marised by arithmetic mean, standard deviation, mini-
mum, 25% quantile, median, 75% quantile, maximum,
and the number of complete and missing observations.
If appropriate, continuous variables can also be pre-
sented in categories. Categorical data are summarised by
the total number of patients in each category and the
number of missing values. Relative frequencies are dis-
played as valid percentage (number of patients divided
by the number of patients with non-missing values).
Analysis of primary endpoint
The primary statistical analyses of steps 1 and 2 will be
by ITT, that is, all randomised patients will be analysed
according to their allocated arm. Changes in the DCL
ADHD + ODD (DBD) Parent scores between T1-
baseline and T2 (after TASH/waiting) or T2 (after
TASH) and T3, respectively, will be evaluated in separ-
ate mixed-effects models for repeated measures
(MMRM). The MMRMs will include fixed categorical
effects of treatment, centre, visit and treatment-by-visit
interaction, and continuous, fixed covariates of baseline
and baseline-by visit interaction. Further covariates pre-
dictive of missingness will be included based on a pre-
specified selection strategy, to correct for potential bias
arising from missing data.
Unstructured covariance matrices will be used to
model within-patient correlations. The primary treat-
ment comparisons of the change scores at T2 and T3
will be based on least-squares means with two-sided
95% confidence intervals without correction for multiple
testing. Other possibly relevant covariates may be con-
sidered as well. Subgroup analyses will be conducted in
an exploratory manner by including interaction terms in
the MMRMs. These will focus on the analyses of pa-
tients’ and parents’ comorbidity. In addition, gender ef-
fects will be investigated as prognostic and predictive
factors. Exploratory within-subjects comparisons
(change in step 1 compared to change in step 2) will also
be also carried out in MMRMs. Secondary efficacy end-
points derived from other scale scores will be analysed
in the same manner, i.e. with the same type of linear
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model. Follow-up of full responders after step 1 will be
evaluated descriptively. No interim analysis for efficacy
will be performed.
Safety/tolerability analyses will be carried out in all pa-
tients for whom one of the randomised treatments was
started, according to treatment received.
Analysis of secondary endpoints
Secondary endpoints will be analysed descriptively in a
similar fashion to the primary outcome. Scores will be
calculated according to the respective manuals.
The analysis of the change between T1-baseline and
T2 (after TASH/waiting) and T3 (after TAU/PMPTT)
comprises the analysis of the primary endpoint for con-
tinuous measurements (DCL-ADHS, DCL-SSV, FBB-
ADHS, FBB- SSV, CU-Preschool, CBCL/1,5–5, CTRF,
WFIRS, KIDDY KINDL, FZEV, FPNE, VER). In addition,
for DCL-ADHS and the measurements listed above,
change between T2 and T3 in patients without ADHD/
ODD (at T2) will be evaluated. Treatment effects will be
calculated with two-sided 95% confidence intervals.
The within-patient changes between T2 and T3 in pa-
tients without ADHD/ODD (at T2) in continuous end-
points will be analysed using linear regression adjusted
for the baseline measurement and study centre.
The difference in the CGI between T1 and T2 and
between T2 and T3 in the randomised steps will be ana-
lysed using the Mann-Whitney U test. The within-
patient difference in the CGI will be analysed using the
Wilcoxon signed-rank test.
Possible predictors of the DCL-ADHD score will be
analysed using linear regression.
Legal and ethical foundation
Before trial start, all relevant documents were submitted
to the local Ethics Committee responsible for the re-
spective participating centres. The primary vote on the
study was obtained from the Ethics Committee of the
Medical Faculty of the Philipps University of Marburg.
For changes to the trial protocol that are formal in na-
ture or include relevant changes for participants, the
ethics committees have to vote anew.
Discussion
ESCApreschool (investigating 3–6-year-old preschool
children with ADHD) is one part of the multicentre
study ESCAlife, which examines clinical care for chil-
dren, adolescents and adults with ADHD to optimize
evidence-based personalised stepped care approaches
across different age groups (see also [37–39]).
Early onset, high prevalence and persistence, and devel-
opmental comorbidity make ADHD a psychosocially
impairing and cost-intensive mental disorder. Despite con-
tinuous treatment research, there is still a substantial need
to optimise individualised treatment strategies in order to
improve outcomes and reduce the economic burden. By
covering the full spectrum of ADHD at all ages, the consor-
tium will be able to make significant recommendations for
improving ADHD treatment in routine clinical care.
Clinical guidelines recommend an adaptive treatment
and a stepped care approach for the treatment of
ADHD/ODD [12]. However, this approach has not yet
been empirically validated. The main goal of ESCApre-
school is therefore to assess the efficacy of a stepped
care approach in children with ADHD/ODD aged 3–6
years and to identify predictors as well as moderators of
treatment outcome. The design combines two RCTs.
The first aims to analyse the efficacy of the low-
threshold TASH intervention by means of a randomised
waiting control design and to identify predictors of re-
sponse. Partial and non-responders to TASH take part
in a second RCT, which compares the effects of an in-
tense behaviour therapy addressing parents, children and
preschool teachers with TAU. Thus, the design allows
for the evaluation of the additional effects of behaviour
therapy and TAU in preschool children with ADHD/
ODD who did not sufficiently respond to the low-
threshold intervention in step 1 of the study.
The results will improve future guidelines on the
treatment of preschool-age children with ADHD
and/or ODD. Moreover, the findings may also be
used to develop usable, potentially more cost-
effective, individualised stepped care pathways for
young children with ADHD/ODD. The evaluation of
predictors of treatment response will help to iden-
tify indications for specific treatments during the
therapy process. Resource-intensive therapeutic in-
terventions can then be specifically directed at indi-
viduals who will probably not respond to or benefit
from low-threshold treatment. This would help to
distribute resources efficiently and improve treat-
ment for preschool psychiatric patients. Such a tar-
geted, resource-friendly use of interventions will
help children with ADHD, their families, preschool
teachers, peers, the health care system and society
as a whole.
Trial status
The trial was registered at the German Clinical Trials
Register (DRKS) as a Current Controlled Trial under
DRKS00008971 on 1 October 2015. This manuscript
is based on protocol version 3 (14 October 2016). Re-
cruitment started January 2016 with the first patient
enrolled on 29. June 2016 (first patient in). The mile-
stone of 75% (150 patients) was reached in June 2019.
Recruitment for this trial is ongoing. Recruitment will
be completed in approximately December 2019.
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Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-019-3872-8.
Additional file 1: Table S1. Overview of the telephone-assisted self-
help (TASH) booklets for preschool teachers.
Additional file 2: Figure S1. Time schedule with an overview of
outcome measures, predictors and eligibility criteria.
Additional file 3. SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents.
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